Association between polymorphisms in the Toll-like receptor 4, CD14, and CARD15/NOD2 and inflammatory bowel disease in the Greek population

Table 1 TLR4 Asp299Gly and Thr399Ile genotype carriers in CD and UC patients and healthy individuals.

Group	TLR4 Asp299Gly genotype					TLR4 Thr399Ile genotype
	Asp/Asp	Asp/Gly	Gly/Gly	299Gly allelefrequencies (%)	OR	Thr/Thr	Thr/Ile	Ile/Ile	399Ile allelefrequencies (%)	OR
CD	103	15	2	7.92	2.78a	119	1	0	0.42	0.41a
UC	79	6	0	3.53	1.18	82	3	0	1.76	1.78
Controls	95	4	1	3	98	2	0	1

^aP<0.05 vs control group.

Table 2 Allele and genotype frequencies of the promoter polymorphism at position -159 of the CD14 gene in CD and UC patients and healthy controls.

Group	Alleles				Genotypes
	C	T	T allelefrequencies (%)	OR	CC	CT	TT	TT genotype frequencies (%)	OR
CD	119	121	50.42	1.73b	33	53	34	28.33	1.93a
UC	102	68	40	1.13	32	38	15	17.65	1.046
Controls	126	74	37		43	40	17	17

^aP<0.05, ^bP<0.01, vs control group.

Table 3 NOD2/CARD15 mutant allele frequencies in Crohn’s disease (CD) patients, in ulcerative colitis (UC) patients and controls.

Samples		Genotype			Allele frequency (%)	OR
		1	2	3
R702W	CD	96	24	0	10	11.05b
	UC	73	12	0	7.1	7.52b
	Control	98	2	0	1
G908R	CD	87	32	1	14.2	4.51b
	UC	63	21	1	13.5	4.31b
	Control	93	7	0	3.5
L1007fsincC	CD	79	39	2	17.9	3.42b
	UC	79	6	0	3.5	0.57
	Control	88	12	0	6

1: homozygous wild-type; 2: heterozygous; 3: homozygous mutant,

^bP<0.01 vs UC group and control group.

Table 4 Allele and genotype frequencies of the promoter polymorphism at position -159 of the CD14 gene.

CD14 genotypes	Genotyped for the CARD15/NOD2 gene
	CD		UC		Controls
	No variant (n = 47)	At least one variant (n= 73)	No variant (n= 49)	At least one variant (n= 36)	No variant (n= 81)	At least onevariant (n = 19)
CC	17	16	18	14	34	9
CT	21	32	23	15	31	9
TT, n (%)	9 (19.1)	25 (34.2) (P = 0.012)a	8 (16.3)	7 (19.4) (P = 0.156)	16 (19.7)	1 (5.3)
CD14 Alleles
C, n (%)	55 (58.5)	64 (43.8)	59 (60.2)	43 (59.7)	99 (61.1)	27 (71)
T, n (%)	39 (41.5)	82 (56.2) (P = 0.003)b	39 (39.8)	29 (40.3) (P = 0.24)	63 (38.8)	11 (28.9)

^aP<0.05,

^bP<0.01 vs control group.